JP2006525995A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525995A5
JP2006525995A5 JP2006507483A JP2006507483A JP2006525995A5 JP 2006525995 A5 JP2006525995 A5 JP 2006525995A5 JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006525995 A5 JP2006525995 A5 JP 2006525995A5
Authority
JP
Japan
Prior art keywords
use according
cells
therapeutic agent
antibody
allogeneic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006507483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525995A (ja
Filing date
Publication date
Priority claimed from US10/404,662 external-priority patent/US20040197312A1/en
Application filed filed Critical
Publication of JP2006525995A publication Critical patent/JP2006525995A/ja
Publication of JP2006525995A5 publication Critical patent/JP2006525995A5/ja
Withdrawn legal-status Critical Current

Links

JP2006507483A 2003-04-02 2004-03-24 サイトカイン発現細胞ワクチンの組み合わせ Withdrawn JP2006525995A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/404,662 US20040197312A1 (en) 2003-04-02 2003-04-02 Cytokine-expressing cellular vaccine combinations
PCT/US2004/008846 WO2004093831A2 (en) 2003-04-02 2004-03-24 Cytokine-expressing cellular vaccine combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011175553A Division JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ

Publications (2)

Publication Number Publication Date
JP2006525995A JP2006525995A (ja) 2006-11-16
JP2006525995A5 true JP2006525995A5 (cg-RX-API-DMAC7.html) 2007-05-24

Family

ID=33096962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006507483A Withdrawn JP2006525995A (ja) 2003-04-02 2004-03-24 サイトカイン発現細胞ワクチンの組み合わせ
JP2011175553A Expired - Fee Related JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ
JP2014084319A Pending JP2014169299A (ja) 2003-04-02 2014-04-16 サイトカイン発現細胞ワクチンの組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011175553A Expired - Fee Related JP5607000B2 (ja) 2003-04-02 2011-08-11 サイトカイン発現細胞ワクチンの組み合わせ
JP2014084319A Pending JP2014169299A (ja) 2003-04-02 2014-04-16 サイトカイン発現細胞ワクチンの組み合わせ

Country Status (5)

Country Link
US (3) US20040197312A1 (cg-RX-API-DMAC7.html)
EP (3) EP2574346A1 (cg-RX-API-DMAC7.html)
JP (3) JP2006525995A (cg-RX-API-DMAC7.html)
CA (1) CA2519563A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004093831A2 (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7297204B2 (en) 2004-02-18 2007-11-20 Meadwestvaco Corporation Water-in-oil bituminous dispersions and methods for producing paving compositions from the same
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
US20100015143A1 (en) * 2006-03-22 2010-01-21 Tracy Hussell Compositions and Methods Relating to Modulation of Immune System Components
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
MX2008013993A (es) 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
CA2665068C (en) * 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
US20080181874A1 (en) * 2007-01-29 2008-07-31 Alexander Kharazi Cell composition and method for treating cancer
US20090028857A1 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009032256A2 (en) * 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
CA2798074A1 (en) * 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
US9572894B2 (en) * 2010-10-18 2017-02-21 The University Of Iowa Research Foundation Biodegradable particulate formulations
EP2753348B1 (en) 2011-09-05 2019-12-11 Hanmi Science Co., Ltd. Pharmaceutical compositions comprising an interferon alpha conjugate and gemcitabine for the treatment of cancer
US9308253B2 (en) * 2011-09-19 2016-04-12 The Johns Hopkins University Cancer immunotherapy
SG11201407875UA (en) * 2012-06-08 2014-12-30 Aduro Biotech Compostions and methods for cancer immunotherapy
KR20150038066A (ko) * 2012-07-30 2015-04-08 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
EP2982681B8 (en) 2013-03-29 2018-11-07 Sumitomo Dainippon Pharma Co., Ltd. Wt1-antigen peptide conjugate vaccine
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
NZ721908A (en) * 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
JP2017526702A (ja) * 2014-09-08 2017-09-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ＰＰＡＲ−γアゴニストを投与する段階を含む、癌を治療する方法
JP6726102B2 (ja) * 2014-10-15 2020-07-22 住友化学株式会社 リチウム二次電池用正極活物質、リチウム二次電池用正極及びリチウム二次電池
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
ES2845727T3 (es) * 2015-02-06 2021-07-27 Heat Biologics Inc Vector que coexpresa una vacuna y moléculas coestimuladoras
CA2978567A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation using plinabulin
AU2016240411A1 (en) * 2015-04-02 2017-10-12 Cancure Limited Agents and compositions for eliciting an immune response
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
KR20180010229A (ko) 2015-05-20 2018-01-30 더 브로드 인스티튜트, 인코퍼레이티드 공유 신생항원
EP3299028B1 (en) * 2015-05-20 2024-10-30 Sumitomo Pharma Co., Ltd. Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
EP3313404B1 (en) * 2015-06-29 2024-09-04 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
AU2016369519B2 (en) 2015-12-16 2023-04-20 Seattle Project Corp. Neoantigen identification, manufacture, and use
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
EP3426271B1 (en) 2016-03-10 2025-08-27 CG Oncology, Inc. Methods of treating solid tumors by combination therapy
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
WO2017223090A1 (en) * 2016-06-21 2017-12-28 The Trustees Of Columbia University In The City Of New York Whole-cell based vaccine against zika virus
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3078744A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2019222423A1 (en) * 2018-05-15 2019-11-21 The Brigham And Women's Hospital, Inc. Compositions and methods related to tumor cell killers and vaccines
US20210177952A1 (en) * 2018-08-16 2021-06-17 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
JP2022552378A (ja) * 2019-10-15 2022-12-15 モデルナティエックス インコーポレイテッド パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ
TWI776276B (zh) * 2019-11-13 2022-09-01 中國醫藥大學 異種組織細胞組合物治療癌症之用途
US20210205428A1 (en) 2019-12-03 2021-07-08 Neuvogen, Inc. Tumor cell vaccines
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) * 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
JPH06501161A (ja) 1990-09-14 1994-02-10 ザ　ジョーンズ　ホプキンス　ユニバーシティー 抗腫瘍免疫性の強化と遺伝子治療のための組成物及び方法
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
PT766745E (pt) * 1995-04-08 2003-02-28 Lg Chemical Ltd ANTICORPO MONOCLONAL ESPECíFICO PARA 4-1BB HUMANO E LINHA CELULAR PARA PRODUCAO DO MESMO
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6805869B2 (en) * 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
CN1232402A (zh) * 1996-10-11 1999-10-20 布里斯托尔-迈尔斯斯奎布公司 免疫调节的方法和组合物
NZ500546A (en) 1997-04-14 2001-09-28 Cell Genesys Inc Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV)
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318372C (en) * 1998-02-02 2008-08-19 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
EP1125133A1 (en) * 1998-11-03 2001-08-22 Cell Genesys, Inc. Novel cancer-associated antigens and methods of their identification
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
ATE397457T1 (de) * 1998-12-03 2008-06-15 Univ California Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AU2002335973A1 (en) * 2001-10-23 2003-05-06 Centre For Translational Research In Cancer A synthetic chimeric fusion protein with immuno-therapeutic uses
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products

Similar Documents

Publication Publication Date Title
JP2006525995A5 (cg-RX-API-DMAC7.html)
Tai et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells
JP2018502120A5 (cg-RX-API-DMAC7.html)
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2007092939A3 (en) Antigenic gm-csf peptides and antibodies to gm-csf
RU2012156903A (ru) Способы комбинированной терапии для лечения пролиферативных заболеваний
RU2019114963A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
Watkins-Yoon et al. CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma
JP2019532047A5 (cg-RX-API-DMAC7.html)
CR20200463A (es) Anticuerpos
ATE412425T1 (de) Neue krebsbehandlung
Pai et al. Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels
JP2014523398A5 (cg-RX-API-DMAC7.html)
EP4371610A3 (en) Topical treatment of inflammatory bowel disease using antibodies and fragments thereof
Jain et al. Radiation therapy as a bridging strategy for refractory diffuse large B cell lymphoma patients awaiting CAR T manufacturing of axicabtagene ciloleucel
WO2011056566A3 (en) Compounds and methods for treatment of cancer
Bell et al. Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy
Wang et al. Cord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case report
Leung Immunotherapy in acute leukemia
Fischer et al. RIG-I-induced type I IFNs promote regeneration of the intestinal stem cell compartment during acute tissue damage
Bardet et al. Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy
Arai et al. Enhanced expression of CXCR4 facilitates the trafficking of anti-C-kit chimeric antigen receptor (CAR) T cells to bone marrow and achieves effective donor stem cell engraftment
Das et al. Blockade of IL-23 Signaling Results in Targeted Protection of the Colon and Allows for Separation of Graft Versus Host and Graft Versus Leukemia Effects.
Cihan et al. 212 Development of EPHA2 CAR T cell therapy for solid tumors